Dagan R - Search Results

1

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).

Simon JK, Staerke NB, Hemming-Harlo M, Layle S, Dagan R, Shekar T, Pedley A, Jumes P, Tamms G, Sterling T, Musey L, Buchwald UK; V114-020 PNEU-TRUE study group. Simon JK, et al. Among authors: dagan r. Vaccine. 2022 Feb 23;40(9):1342-1351. doi: 10.1016/j.vaccine.2021.12.067. Epub 2022 Jan 14. Vaccine. 2022. PMID: 35039194 Clinical Trial.

2

Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy.

Pelton SI, Dagan R, Gaines BM, Klugman KP, Laufer D, O'Brien K, Schmitt HJ. Pelton SI, et al. Among authors: dagan r. Vaccine. 2003 Apr 2;21(15):1562-71. doi: 10.1016/s0264-410x(02)00681-3. Vaccine. 2003. PMID: 12639477

3

The potential indirect effect of conjugate pneumococcal vaccines.

O'Brien KL, Dagan R. O'Brien KL, et al. Among authors: dagan r. Vaccine. 2003 May 16;21(17-18):1815-25. doi: 10.1016/s0264-410x(02)00807-1. Vaccine. 2003. PMID: 12706665 Review.

4

Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.

Dagan R, Givon-Lavi N, Zamir O, Fraser D. Dagan R, et al. Pediatr Infect Dis J. 2003 Jun;22(6):532-40. doi: 10.1097/01.inf.0000069761.11093.c3. Pediatr Infect Dis J. 2003. PMID: 12799510 Clinical Trial.

5

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T. Jódar L, et al. Among authors: dagan r. Vaccine. 2003 Jul 4;21(23):3265-72. doi: 10.1016/s0264-410x(03)00230-5. Vaccine. 2003. PMID: 12804857 Review.

6

Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines.

Dagan R. Dagan R. Commun Dis Intell Q Rep. 2003;27 Suppl:S134-42. Commun Dis Intell Q Rep. 2003. PMID: 12807290 Free article.

7

Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.

Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J. Dagan R, et al. Pediatr Infect Dis J. 2004 Feb;23(2):91-8. doi: 10.1097/01.inf.0000109221.50972.53. Pediatr Infect Dis J. 2004. PMID: 14872172

8

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus.

Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Dagan R, et al. J Infect Dis. 2005 Aug 1;192(3):367-76. doi: 10.1086/431679. Epub 2005 Jun 28. J Infect Dis. 2005. PMID: 15995949

9

Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.

Dagan R, Greenberg D, Weber F. Dagan R, et al. Vaccine. 2005 Oct 25;23(44):5144-8. doi: 10.1016/j.vaccine.2005.06.017. Vaccine. 2005. PMID: 16043271

10

Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine.

Wuorimaa TK, Dagan R, Bailleux F, Haikala R, Ekström N, Eskola J, Yaich M, Käyhty H. Wuorimaa TK, et al. Among authors: dagan r. Vaccine. 2005 Nov 16;23(46-47):5328-32. doi: 10.1016/j.vaccine.2005.06.023. Epub 2005 Jul 14. Vaccine. 2005. PMID: 16118028 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

758 results

Search Page

Filters